Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

3 recruiting

Phase 1

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 1(3)

Phase 2(2)

Loading network data...

Showing 5 of 5 trials

A Study to Evaluate Single and Multiple Doses of TLC-1180 in Healthy Subjects

Role: lead

Phase 1/1b Study of TLC-6740 in Healthy Subjects and Subjects With Obesity, With or Without Diabetes

Role: lead

Phase 2a Study of Safety, Tolerability, and Efficacy of TLC-2716 in Subjects With Hypertriglyceridemia and NAFLD

Role: lead

A Study Evaluating Daily Oral Doses of TLC-3595 in Participants With Insulin Resistance

Role: lead

A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants

Role: lead

All 5 trials loaded